A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Ambu A/S, together with its subsidiaries, researches, develops, manufactures, markets, and sells medical technology solutions in North America, Europe, and internationally. The company offers endoscopy products, including bronchoscopes, video laryngoscopes, rhinolaryngoscopes, duodenoscopes, gastroscopes, cystoscopes, ureteroscopes, and displaying and processing units; neurology products, such as EEG and EMG electrodes, EMG guided injections, and intraoperative monitoring products; and cardiology products comprising ECG electrodes. It also provides airway management and anaesthesia products, which include double and single lumen tubes, endobronchial blockers, laryngeal and face masks, breathing bags, and resuscitators. In addition, the company offers emergency care and training products, such as extrication collars and ALS and BLS training manikins, as well as mobile workstations, IOMs, and patient monitoring and diagnostics devices. Ambu A/S was founded in 1937 and is headquartered in Ballerup, Denmark.
Financial Summary
| Share Statistics | AMBBY | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $3,170.8 | $422.9 | 60% |
|
| Shares Out (Mil) | 40.6 | 41.4 | 42% |
|
| Institutional Ownership | 24.9% | 83.6% | 11% |
|
| Float (Mil) | 177.5 | 34.9 | 72% |
|
| Beta | 1.26 | 0.88 | 74% |
|
| Avg Daily Volume (000s) | 1 | 409 | 4% |
|
| Price Change (52-week) |
(22.5%) | 66.3% | 27% |
|
| Growth | AMBBY | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 11.0% | 11.9% | 62% |
|
| Net Income (5yr) | 20.3% | (5.9%) | 74% |
|
| EPS (5yr) | 18.5% | 10.4% | 66 |
|
| Dividends (5yr) | 7.1% | 0.0% | 55% |
|
| Cash Flow (5yr) | 65.6% | (16.2%) | 96% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | AMBBY | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $942 | $123 | 49% |
|
| Net Income (TTM) (Mil) | $74 | ($9) | 58% |
|
| EPS (TTM) | $0.277 | ($0.400) | 49% |
|
| Operating Cash Flow (TTM) (Mil) | $131 | ($3) | 54% |
|
| Net Cash Flow (TTM) (Mil) | $8 | $1 | 55% |
|
| Long-Term Debt (Q1) (Mil) | $72 | $22 | 42% |
|
| Enterprise Value (Q1) (Mil) | $2,658 | $418 | 53% |
|
| Valuation | AMBBY | Industry Median |
Percentile (All Stocks) |
|
| P/B | na | 3.13 | na |
|
| P/E | na | 28.1 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.7 | na |
|
| Ratios | AMBBY | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 60.0% | 58.7% | 73% |
|
| Net Margin | 7.8% | (6.9%) | 57% |
|
| ROA | 6.5% | (12.3%) | 77% |
|
| ROE | 8.2% | (12.3%) | 52% |
|
| Liabilities to Assets | 19.8% | 46.0% | 13% |
|
| F-Score | na | 4 | na |
|
Ambu A/S did not pass any screens on 8/21/2026.
